Loading clinical trials...
Loading clinical trials...
A Phase II Multicentre Trial for the Use of 5-ALA Paediatric Patients With High Grade Brain Tumours
The aim of the study is to examine the safety and feasibility of using 5-ALA in children who have MRI scans showing an aggressive looking brain tumour. It will also study if 5-ALA can help the surgeon achieve maximal tumour removal and discriminate between normal brain tissue and tumour. Patients will be between 3-18 years (inclusive) and all patients will receive 5-ALA 3-6 hours prior to resection surgery.
Age
3 - 18 years
Sex
ALL
Healthy Volunteers
No
Nottingham Children's Hospital
Nottingham, United Kingdom
Start Date
March 25, 2025
Primary Completion Date
June 30, 2026
Completion Date
December 30, 2026
Last Updated
March 27, 2025
80
ESTIMATED participants
5-ALA (Gliolan)
DRUG
Lead Sponsor
University College, London
Collaborators
NCT05839379
NCT06962215
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05588141